$BZYR
BURZYNSKI RESEARCH INSTITUTE INC

2022 Form 10-K Financial Statement

#000155837022009398 Filed on May 26, 2022

View on sec.gov

Income Statement

Concept 2022 2021 Q1 2021
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $217.2K $50.00K $278.8K
YoY Change -22.12% -6.99% -35.43%
% of Gross Profit
Research & Development $759.5K $200.0K $1.023M
YoY Change -25.75% -13.42% -14.98%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $976.7K $250.0K $1.302M
YoY Change -24.97% -12.21% -20.38%
Operating Profit -$976.7K -$1.302M
YoY Change -24.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $100.0K $97.77K
YoY Change -100.0% 19900.0% 19454.0%
Pretax Income -$976.7K -$150.0K -$1.204M
YoY Change -18.88% -47.23% -26.34%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$976.7K -$150.0K -$1.204M
YoY Change -18.88% -47.23% -26.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$1.141K -$0.01
COMMON SHARES
Basic Shares Outstanding 131.4M 131.4M
Diluted Shares Outstanding 131.4M 131.4M

Balance Sheet

Concept 2022 2021 Q1 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.380K $60.00
YoY Change 5533.33% -62.5%
Cash & Equivalents $3.380K $62.00 $60.00
Short-Term Investments
Other Short-Term Assets $1.280K $890.00
YoY Change 43.82% -95.48%
Inventory
Prepaid Expenses $894.00
Receivables
Other Receivables
Total Short-Term Assets $4.660K $956.00 $960.00
YoY Change 385.42% 497.5% -95.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.660K $956.00 $960.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $4.660K $956.00 $960.00
YoY Change 385.42% -95.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $32.51K $32.51K
YoY Change -100.0% -46.54%
Accrued Expenses $3.460K $14.29K $14.29K
YoY Change -75.79% -87.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.460K $50.00K $46.80K
YoY Change -92.61% -72.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.460K $50.00K $46.80K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.460K $46.80K $46.80K
YoY Change -92.61% -72.86%
SHAREHOLDERS EQUITY
Retained Earnings -$124.9M
YoY Change
Common Stock $124.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.210K -$45.84K -$45.84K
YoY Change
Total Liabilities & Shareholders Equity $4.660K $956.00 $960.00
YoY Change 385.42% -95.16%

Cashflow Statement

Concept 2022 2021 Q1 2021
OPERATING ACTIVITIES
Net Income -$976.7K -$150.0K -$1.204M
YoY Change -18.88% -47.23% -26.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$325.1K -$45.35K -$394.4K
YoY Change -17.57% -54.7% -25.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 328.4K 44.45K 394.3K
YoY Change -16.7% -55.58% -25.55%
NET CHANGE
Cash From Operating Activities -325.1K -45.35K -394.4K
Cash From Investing Activities
Cash From Financing Activities 328.4K 44.45K 394.3K
Net Change In Cash 3.320K -900.0 -101.0
YoY Change -3387.13% 1700.0% -81.3%
FREE CASH FLOW
Cash From Operating Activities -$325.1K -$45.35K -$394.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022 dei Auditor Firm
AuditorFirmId
342
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131448444
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131448444
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0000724445
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Registrant Name
EntityRegistrantName
BURZYNSKI RESEARCH INSTITUTE INC
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-02-28
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-23425
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0136810
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
9432 Katy Freeway
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77055
CY2022 dei City Area Code
CityAreaCode
713
CY2022 dei Local Phone Number
LocalPhoneNumber
335-5697
CY2022 dei Security12g Title
Security12gTitle
Common Stock, $.001 par value
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Public Float
EntityPublicFloat
798986
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131448444
CY2022 dei Auditor Name
AuditorName
Pannell Kerr Forster
CY2022 dei Auditor Location
AuditorLocation
Houston, Texas
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3382
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1279
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
894
CY2022Q1 us-gaap Assets Current
AssetsCurrent
4661
CY2021Q1 us-gaap Assets Current
AssetsCurrent
956
CY2022Q1 us-gaap Assets
Assets
4661
CY2021Q1 us-gaap Assets
Assets
956
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
32512
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3455
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14287
CY2022Q1 us-gaap Liabilities
Liabilities
3455
CY2021Q1 us-gaap Liabilities
Liabilities
46799
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131448444
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
131449
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
131449
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125708240
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
124684535
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125838483
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124861827
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4661
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
956
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
759510
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1022951
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
217146
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
278820
CY2022 us-gaap Operating Expenses
OperatingExpenses
976656
CY2021 us-gaap Operating Expenses
OperatingExpenses
1301771
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-976656
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1301771
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
97773
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-976656
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1203998
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-976656
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1203998
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131448444
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-152587
CY2021 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
394268
CY2021 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
916474
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1203998
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-45843
CY2022 bzyr Adjustments To Additional Paid In Capital Cash Contributed
AdjustmentsToAdditionalPaidInCapitalCashContributed
328418
CY2022 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
695287
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-976656
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1206
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-976656
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1203998
CY2022 bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
695287
CY2021 bzyr Clinical Trial Expenses Paid
ClinicalTrialExpensesPaid
916474
CY2021 bzyr Forgiveness Of Accounts Payable And Accrued Expenses
ForgivenessOfAccountsPayableAndAccruedExpenses
-97773
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
385
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18796
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-32512
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-28293
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10832
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
425
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-325098
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-394369
CY2022 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
328418
CY2021 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
394268
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
328418
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
394268
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3320
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-101
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3382
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62
CY2022Q1 bzyr Ownership Interest Percentage Held By Company President And Chairman Of Board
OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard
0.810
CY2022 bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
CY2022 bzyr Number Of Antineoplaston Drugs That Received Fda Approval
NumberOfAntineoplastonDrugsThatReceivedFDAApproval
0
CY2020Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1600000
CY2022 bzyr Number Of Trading Securities
NumberOfTradingSecurities
0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Management Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reported periods. The significant estimates are the allocation of payroll and other expenses between the clinical trial expenses reported with BRI and Dr. Burzynski’s medical practice expenses. Department managers review at least quarterly the duties of each employee in their department and estimate the percentage of time each employee spends between clinical trials and the medical practice. Payroll costs are allocated between clinical trials and the medical practice based on these percentages. Other expenses are allocated based on the percentage of payroll allocated to either clinical trials or the medical practice. Management believes that the estimates and allocations are reasonable. Actual results could differ from these estimates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p>
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
70600
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
70270
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
89050
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
86779
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
205098
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
252840
CY2022 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
205098
CY2021 us-gaap Income Tax Reconciliation Deductions
IncomeTaxReconciliationDeductions
252840
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
-9880
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1884
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9880
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1884
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
116099
CY2021Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
125979
CY2022Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
42603
CY2021Q1 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
42603
CY2022Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
158702
CY2021Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168582
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
158702
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168582
CY2022Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Revenues
Revenues
0
CY2022 us-gaap Revenues
Revenues
0
CY2022 bzyr Percentage Of Future Taxable Income Net Operating Loss Carryforwards
PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards
0.80
CY2022 bzyr Percentage On Net Operating Loss Carryforwards Limit Of Taxable Income Under Coronavirus Aid Relief And Economic Security Act
PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct
0.80
CY2022Q1 bzyr Tax Cuts And Jobs Act Of2017 Net Operating Loss Carryforwards
TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards
473902
CY2022 bzyr Net Operating Loss Carry Forward Indefinitely
NetOperatingLossCarryForwardIndefinitely
78948
CY2022Q1 bzyr Alternative Minimum Tax Credit Carryforwards
AlternativeMinimumTaxCreditCarryforwards
42603
CY2021 bzyr Forgiveness Of Accounts Payable And Accrued Expenses
ForgivenessOfAccountsPayableAndAccruedExpenses
-97773
CY2022 bzyr Forgiveness Of Accounts Payable And Accrued Expenses
ForgivenessOfAccountsPayableAndAccruedExpenses
0

Files In Submission

Name View Source Status
0001558370-22-009398-index-headers.html Edgar Link pending
0001558370-22-009398-index.html Edgar Link pending
0001558370-22-009398.txt Edgar Link pending
0001558370-22-009398-xbrl.zip Edgar Link pending
bzyr-20220228.xsd Edgar Link pending
bzyr-20220228x10k.htm Edgar Link pending
bzyr-20220228x10k_htm.xml Edgar Link completed
bzyr-20220228xex31d1.htm Edgar Link pending
bzyr-20220228xex31d2.htm Edgar Link pending
bzyr-20220228xex32d1.htm Edgar Link pending
bzyr-20220228xex32d2.htm Edgar Link pending
bzyr-20220228_cal.xml Edgar Link unprocessable
bzyr-20220228_def.xml Edgar Link unprocessable
bzyr-20220228_lab.xml Edgar Link unprocessable
bzyr-20220228_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending